Covered recipient · General Payments record
RANA KHOURY
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2019–2024
$961.38
- Reported across 52 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $351.14 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $78.31 | 4 |
| Amgen Inc. | $74.30 | 3 |
| ABBVIE INC. | $65.31 | 3 |
| PFIZER INC. | $48.63 | 3 |
| GlaxoSmithKline, LLC. | $36.28 | 2 |
| Exact Sciences Corporation | $18.31 | 1 |
| Phathom Pharmaceuticals, Inc. | $16.24 | 1 |
| Lilly USA, LLC | $13.76 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.25 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104067578 | CMS |
| ABBVIE INC. | $20.98 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104067580 | CMS |
| ABBVIE INC. | $23.08 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104067582 | CMS |
| Amgen Inc. | $22.38 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117597866 | CMS |
| Amgen Inc. | $24.66 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117597868 | CMS |
| Amgen Inc. | $27.26 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117597870 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.92 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105295542 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.67 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104659261 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.87 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104579182 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.85 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105600629 | CMS |
| Exact Sciences Corporation | $18.31 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114733812 | CMS |
| GlaxoSmithKline, LLC. | $21.06 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116703310 | CMS |
| GlaxoSmithKline, LLC. | $15.22 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116688612 | CMS |
| Lilly USA, LLC | $13.76 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135352101 | CMS |
| PFIZER INC. | $20.39 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131634712 | CMS |
| PFIZER INC. | $13.16 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131190331 | CMS |
| PFIZER INC. | $15.08 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131241944 | CMS |
| Phathom Pharmaceuticals, Inc. | $16.24 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151081699 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.